Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
8.96
-0.78 (-8.01%)
At close: Feb 28, 2025
-43.65%
Market Cap 283.59M
Revenue (ttm) n/a
Net Income (ttm) -58.71M
Shares Out 21.15M
EPS (ttm) -2.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,374
Average Volume 5,409
Open 9.06
Previous Close 9.74
Day's Range 8.96 - 9.06
52-Week Range n/a
Beta 0.15
RSI 46.10
Earnings Date Feb 20, 2025

About Curasight

Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue. The company focuses on gen... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.